Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1740

1.

Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.

Nikiforuk A, Kos T, Hołuj M, Potasiewicz A, Popik P.

Neuropharmacology. 2015 Jul 29. pii: S0028-3908(15)30041-1. doi: 10.1016/j.neuropharm.2015.07.034. [Epub ahead of print]

PMID:
26232639
2.

Plant alkaloids as drug leads for Alzheimer's disease.

Ng YP, Cho T, Or T, Ip NY.

Neurochem Int. 2015 Jul 25. pii: S0197-0186(15)30020-6. doi: 10.1016/j.neuint.2015.07.018. [Epub ahead of print]

PMID:
26220901
3.

Effect of galantamine on adjuvant-induced arthritis in rats.

Gowayed MA, Refaat R, Ahmed WM, El-Abhar HS.

Eur J Pharmacol. 2015 Jul 17;764:547-553. doi: 10.1016/j.ejphar.2015.07.038. [Epub ahead of print]

PMID:
26189022
4.

A fluorescence assay for measuring acetylcholinesterase activity in rat blood and a human neuroblastoma cell line (SH-SY5Y).

Santillo MF, Liu Y.

J Pharmacol Toxicol Methods. 2015 Jul 9;76:15-22. doi: 10.1016/j.vascn.2015.07.002. [Epub ahead of print]

PMID:
26165232
6.

Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?

Ehret MJ, Chamberlin KW.

Clin Ther. 2015 Jun 26. pii: S0149-2918(15)00852-8. doi: 10.1016/j.clinthera.2015.05.510. [Epub ahead of print] Review.

PMID:
26122885
7.

Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases.

Fornaguera C, Feiner-Gracia N, Calderó G, García-Celma MJ, Solans C.

Nanoscale. 2015 Jul 28;7(28):12076-84. doi: 10.1039/c5nr03474d. Epub 2015 Jun 29.

PMID:
26118655
8.

Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.

Oka M, Nakaaki S, Negi A, Miyata J, Nakagawa A, Hirono N, Mimura M.

Psychogeriatrics. 2015 Jun 26. doi: 10.1111/psyg.12132. [Epub ahead of print]

PMID:
26114924
9.

[Update on the diagnosis and management of vascular cognitive impairment].

Demey I, Somale V, Allegri RF.

Vertex. 2014 Nov-Dec;25(118):437-46. Spanish.

PMID:
26098823
10.

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer's disease.

Woo FY, Basri M, Masoumi HR, Ahmad MB, Ismail M.

Int J Nanomedicine. 2015 Jun 5;10:3879-86. doi: 10.2147/IJN.S80253. eCollection 2015.

11.

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.

Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O'Brien JT.

Am J Psychiatry. 2015 Aug 1;172(8):731-42. doi: 10.1176/appi.ajp.2015.14121582. Epub 2015 Jun 18.

PMID:
26085043
12.

Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures.

Buendia I, Parada E, Navarro E, León R, Negredo P, Egea J, López MG.

Mol Neurobiol. 2015 Jun 17. [Epub ahead of print]

PMID:
26081146
13.

Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.

Smith ME, Haney E, McDonagh M, Pappas M, Daeges M, Wasson N, Fu R, Nelson HD.

Ann Intern Med. 2015 Jun 16;162(12):841-50. doi: 10.7326/M15-0114.

14.

The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.

Deardorff WJ, Feen E, Grossberg GT.

Drugs Aging. 2015 Jul;32(7):537-47. doi: 10.1007/s40266-015-0273-x.

PMID:
26033268
15.

Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats.

Nikiforuk A, Kos T, Potasiewicz A, Popik P.

Eur Neuropsychopharmacol. 2015 Apr 30. pii: S0924-977X(15)00123-6. doi: 10.1016/j.euroneuro.2015.04.018. [Epub ahead of print]

PMID:
26003081
16.

Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial.

Shimizu S, Kanetaka H, Hirose D, Sakurai H, Hanyu H.

Dement Geriatr Cogn Dis Extra. 2015 Apr 10;5(1):135-46. doi: 10.1159/000375527. eCollection 2015 Jan-Apr.

17.

Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use.

Wübbeler M, Wucherer D, Hertel J, Michalowsky B, Heinrich S, Meyer S, Schaefer-Walkmann S, Hoffmann W, Thyrian JR.

BMC Health Serv Res. 2015 May 22;15:205. doi: 10.1186/s12913-015-0855-7.

18.

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis.

Atri A, Hendrix SB, Pejović V, Hofbauer RK, Edwards J, Molinuevo JL, Graham SM.

Alzheimers Res Ther. 2015 May 18;7(1):28. doi: 10.1186/s13195-015-0109-2. eCollection 2015.

19.

Nicotinic receptor-dependent and -independent effects of galantamine, an acetylcholinesterase inhibitor, on the non-neuronal acetylcholine system in C2C12 cells.

Oikawa S, Mano A, Iketani M, Kakinuma Y.

Int Immunopharmacol. 2015 May 12. pii: S1567-5769(15)00221-0. doi: 10.1016/j.intimp.2015.04.057. [Epub ahead of print]

PMID:
25979761
20.

Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease.

Tokuchi R, Hishikawa N, Matsuzono K, Takao Y, Wakutani Y, Sato K, Kono S, Ohta Y, Deguchi K, Yamashita T, Abe K.

Geriatr Gerontol Int. 2015 May 8. doi: 10.1111/ggi.12488. [Epub ahead of print]

PMID:
25952367
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk